VISION Trial: Lutetium-177–PSMA-617 for Metastatic Prostate Cancer

The VISION trial was a phase 3 international, open-label study that aimed to evaluate the efficacy of Lutetium-177 (177Lu)–PSMA-617, a radioligand therapy, in patients with metastatic castration-resistant prostate cancer (mCRPC). This type of cancer remains fatal despite recent advancements, and prostate-specific membrane antigen (PSMA) is highly expressed in mCRPC. The trial enrolled patients who had […]